Alcohol-related liver disease — management
ArLD · Gastroenterology
Physician-written · Verified by three sets of doctors · Reviewed November 2026
Bedside summary
A spectrum from steatosis through steatohepatitis to fibrosis and cirrhosis driven by chronic alcohol use; abstinence is the single most effective intervention and alters prognosis at every stage.
Red flags
- Jaundice with coagulopathy (severe alcohol-related hepatitis/decompensation)
- Encephalopathy or GI bleeding
- Features of Wernicke's (confusion, ophthalmoplegia, ataxia)
- Rapidly rising bilirubin
Assessment
Differential diagnosis
- MASLD/metabolic steatohepatitis
- Viral hepatitis
- Haemochromatosis
- Autoimmune/drug-induced liver injury
- Acute alcohol-related hepatitis (distinct acute syndrome)
Investigations
- LFTs (AST:ALT ratio >2 typical), GGT, FBC (macrocytosis, thrombocytopenia)
- Liver screen to exclude other causes (viral, autoimmune, iron, ceruloplasmin)
- Transient elastography (FibroScan) for fibrosis staging
- Ultrasound ± cross-sectional imaging; AFP if cirrhotic (HCC surveillance)
- Alcohol use assessment (AUDIT), nutritional and thiamine status
Management
- Establish diagnosis and stage fibrosis non-invasively; exclude co-existing liver disease
- Support alcohol abstinence — the decisive intervention — with specialist alcohol services
- Manage/anticipate alcohol withdrawal with a symptom-triggered benzodiazepine regimen
- Give parenteral thiamine to prevent Wernicke's encephalopathy before carbohydrate
- Optimise nutrition — high calorie/protein intake, treat micronutrient deficiencies
- Treat the metabolic co-factors (obesity, diabetes) that accelerate fibrosis
- Vaccinate against hepatitis A and B
- Screen for and manage cirrhosis complications (varices, ascites, encephalopathy)
- Enrol cirrhotic patients in 6-monthly HCC surveillance ultrasound
- Identify acute alcohol-related hepatitis (distinct severe syndrome) needing specific assessment
- Provide long-term relapse-prevention pharmacotherapy and psychosocial support
- Refer for transplant assessment in decompensated disease with abstinence
Drugs & doses
Pabrinex (thiamine-rich B/C vitamins) IV then oral thiamine 100 mg three times daily
Chlordiazepoxide 10–40 mg PO (symptom-triggered withdrawal regimen)
Acamprosate 666 mg PO three times daily (relapse prevention)
Baclofen 5–10 mg PO three times daily (relapse prevention in cirrhosis)
Disposition
Joint hepatology and alcohol-services management; admit decompensation/withdrawal; transplant referral for abstinent decompensated patients.
Complications & pitfalls
- Cirrhosis and portal hypertension
- Hepatocellular carcinoma
- Wernicke-Korsakoff syndrome
- Alcohol withdrawal seizures/delirium tremens
- Malnutrition and sarcopenia
Exam pearls
- Give thiamine before any glucose to avoid precipitating Wernicke's encephalopathy
- An AST:ALT ratio >2 with raised GGT and macrocytosis points to alcohol as the cause
- Abstinence improves survival at every disease stage, even in advanced cirrhosis
- Baclofen is a preferred relapse-prevention agent in decompensated cirrhosis
Disclaimer: Educational decision support for qualified clinicians and students — not a substitute for clinical judgement, local protocols or a full drug reference. Confirm every dose and contraindication against your formulary before prescribing.